Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Biliary Diseases Clear all
Completed Phase 1Phase 2 Interventional Results available

Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis

NCT01601652
View directory record Official record
Conditions
Parenteral Nutrition Associated Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
Arthur J De Lorimier
Other
Eligibility
Up to 1 Year
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 26, 2026, 2:51 PM EDT
Completed Not applicable Interventional

Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD

NCT01673269
View directory record Official record
Conditions
Choledocholithiasis, Cholangiocarcinoma, Benign Stricture of Common Bile Duct
Interventions
Blood culture ( aerobic and anaerobic)
Other
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 26, 2026, 2:51 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

NCT00406237
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
tigecycline
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Saint Paul, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2011 · Synced Sep 26, 2026, 2:51 PM EDT
Terminated No phase listed Observational

Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

NCT04561453
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer, Intrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Bile Duct Cancer
Interventions
Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 26, 2026, 2:51 PM EDT
Completed Not applicable Interventional Results available

FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis

NCT00590395
View directory record Official record
Conditions
Cholecystitis
Interventions
18FDG (an FDA-approved radiopharmaceutical)
Drug
Lead sponsor
Alan D. Waxman, M.D.
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 26, 2026, 2:51 PM EDT
Completed No phase listed Observational Results available

Laparoscopic Versus Transabdominal Ultrasound in Morbidly Obese Patients

NCT00971750
View directory record Official record
Conditions
Cholelithiasis, Ultrasonography, Laparoscopic Gastric Bypass
Interventions
Not listed
Lead sponsor
Gundersen Lutheran Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Sep 26, 2026, 2:51 PM EDT
Completed Phase 2 Interventional

Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer

NCT00660140
View directory record Official record
Conditions
Cholangiocarcinoma, Gallbladder Cancer
Interventions
Gemcitabine, Carboplatin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 26, 2026, 2:51 PM EDT
Completed No phase listed Observational

Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder

NCT00489515
View directory record Official record
Conditions
Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 26, 2026, 2:51 PM EDT
Recruiting Phase 1 Interventional

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

NCT06825559
View directory record Official record
Conditions
Cholestatic Liver Disease
Interventions
Saroglitazar Magnesium 1 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 26, 2026, 2:51 PM EDT
Completed Phase 1Phase 2 Interventional

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04666688
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma, Head and Neck Cancer, Colorectal Cancer
Interventions
LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel
Drug
Lead sponsor
PureTech
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 26, 2026, 2:51 PM EDT
Completed Not applicable Interventional Results available

SILS™ Port Laparoscopic Cholecystectomy Post Market Study

NCT00832767
View directory record Official record
Conditions
Gallbladder Disease
Interventions
SILS™ port laparoscopic cholecystectomy, Four Port Laparoscopic Cholecystectomy
Procedure
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 85 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
New Haven, Connecticut • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 26, 2026, 2:51 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

NCT07229911
View directory record Official record
Conditions
Healthy Volunteers, Primary Sclerosing Cholangitis
Interventions
TAK-781, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 68 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 26, 2026, 2:51 PM EDT
Completed No phase listed Observational

Brain Manganese Deposition in High Risk Neonates

NCT00392977
View directory record Official record
Conditions
Necrotizing Enterocolitis, Digestive System Abnormalities, Cholestasis
Interventions
remove Mn from PN if evidence of increased brain Mn on MRI
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
30 Days to 12 Months
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 26, 2026, 2:51 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

NCT06525311
View directory record Official record
Conditions
Primary Biliary Cholangitis, Compensated Cirrhosis
Interventions
K-808
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Chandler, Arizona • Coronado, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 26, 2026, 2:51 PM EDT
Terminated Phase 3 Interventional Results available

To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

NCT06488911
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
FDC tablet (OCA 5 mg + BZF 400 mg SR)
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Coronado, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 26, 2026, 2:51 PM EDT
Recruiting Phase 1 Interventional

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

NCT06564623
View directory record Official record
Conditions
Biliary Tract Cancers
Interventions
mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 26, 2026, 2:51 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

NCT04482309
View directory record Official record
Conditions
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
12
States / cities
Duarte, California • Santa Rosa, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 26, 2026, 2:51 PM EDT
Not listed No phase listed Observational

T-EUS for Gastrointestinal Disorders: A Multicenter Registry

NCT01522573
View directory record Official record
Conditions
Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Cancer, Biliary Stricture, Biliary Obstruction, Stent Obstruction, Proximal Duct Stricture, Distal Duct Stricture, Ampullary Cancer, Biliary Sphincter Stenosis, Impacted Stones, Chronic Pancreatitis, Peri-ampullary Diverticula, Altered Anatomy
Interventions
EUS guided ERCP
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Sep 26, 2026, 2:51 PM EDT
Recruiting Phase 3 Interventional

Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy

NCT07424677
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Saroglitazar Magnesium 1 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lakewood Rch, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 26, 2026, 2:51 PM EDT
Active, not recruiting Phase 3 Interventional

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Mobile, Alabama • Orange, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 26, 2026, 2:51 PM EDT
Completed Not applicable Interventional

PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer

NCT02088775
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Metastatic Extrahepatic Bile Duct Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Stage D Adult Primary Liver Cancer (BCLC), Unspecified Adult Solid Tumor, Protocol Specific
Interventions
PET scan, CT Scan, hepatic artery embolization
Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 26, 2026, 2:51 PM EDT
Not listed Phase 4 Interventional

Antibiotics to Decrease Post ERCP Cholangitis

NCT03087656
View directory record Official record
Conditions
Cholangitis
Interventions
Ceftriaxone, Levofloxacin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 26, 2026, 2:51 PM EDT
Terminated Not applicable Interventional Results available

Patency of a Prototype Large Plastic Biliary Stent in the Palliation of Malignant Distal Biliary Strictures.

NCT01590394
View directory record Official record
Conditions
Stricture, Obstruction, Cancer
Interventions
Large plastic biliary stent
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 26, 2026, 2:51 PM EDT
Completed Phase 1 Interventional

PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

NCT00055705
View directory record Official record
Conditions
Cancer
Interventions
PV701
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 26, 2026, 2:51 PM EDT